Candel Therapeutics, Inc.
13 clinical trials · Sponsor
◉ Watch Candel Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) (NCT07660094) | Candel Therapeutics, Inc. | 2026-06-15 |
| A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec (NCT07332000) | Candel Therapeutics, Inc. | 2025-10-30 |
| CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC (NCT04495153) | Candel Therapeutics, Inc. | 2020-10-13 |
| GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas (NCT03576612) | Candel Therapeutics, Inc. | 2018-02-27 |
Track Candel Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.